Drugs / TLPLDC Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02678741 Comparator | Feb 2016 → Oct 2019 | metastatic melanoma | Elios Therapeutics, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLPLDC Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02678741 ↗ |
| Modality | Vaccine | “Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine” NCT02678741 ↗ |